CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July12, 2018, CytoDyn Inc., a Delaware corporation (the “Company”), announced certain leadership changes in connection with the strategic expansion and entry into the letter of intent described in Item 5.02 below.

In connection with such leadership changes, Denis R. Burger, Ph.D. and A. Bruce Montgomery, M.D. have resigned as members of the Company’s Board of Directors. Dr.Burger and Dr.Montgomery informed the Company of their intention to resign at the conclusion of a board meeting on July10, 2018, and the resignations became effective on July11, 2018. The resignations were not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr.Burger has also resigned as Chief Science Officer of the Company, which is not an executive officer position, but will continue to serve as a scientific consultant to the Company with respect to PRO 140 for human immunodeficiency virus (“HIV”) and non-HIV development programs.

In connection with the resignations of Dr.Burger and Dr.Montgomery, on July10, 2018, the Company’s Board of Directors approved a motion to accelerate all outstanding unvested stock options held by Dr.Burger and Dr.Montgomery, to vest immediately upon the effectiveness of their resignations and to retain the stock options’ exercise period through their respective expiration date. Stock options covering 500,000 shares held by Dr.Burger and stock options covering 100,000 shares held by Dr.Montgomery were subject to acceleration. The terms of the stock options remained otherwise unchanged.

Also, effective July11, 2018, Anthony D. Caracciolo resigned as Executive Chairman of the Company, which is an executive officer position. Mr.Caracciolo will continue to serve as a member and the non-executive Chairman of the Company’s Board of Directors.

Item 5.02Regulation FD Disclosure.

On July12, 2018, CytoDyn Inc., a Delaware corporation (the “Company”), issued press releases relating to the announcements described in Item 5.02 above and Item 5.02 below. Copies of the press releases are furnished as Exhibits99.1 and 99.2 to this Form 8-K.

Item 5.02Other Events.

On July12, 2018, the Company announced a strategic expansion of its clinical focus to include the evaluation of PRO 140 in certain cancers and immunological indications where CCR5 antagonism has shown initial promise.

In connection with such expansion, on July12, 2018, the Company signed a non-binding letter of intent regarding a proposed acquisition of intellectual property and other assets of ProstaGene LLC (“ProstaGene”), a privately held company focused on prostate cancer diagnostics and therapeutics aimed at blocking cancer metastasis by blocking CCR5. At the same time, the Company remains committed to advancing its clinical programs with PRO 140 in HIV and graft-versus-host disease (“GvHD”), and is continuing with its previously announced plans to submit a Biologics License Application to the U.S. Food and Drug Administration (the “FDA”) for PRO 140 as a combination therapy for HIV.

As part of the proposed transaction with ProstaGene, Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., the Chief Executive Officer of ProstaGene and President of the Pennsylvania Cancer and Regenerative Medicine Research Center, will join the Company as Chief Medical Officer. It is also expected that Dr.Pestell will join the Company’s Board of Directors at the closing of the transaction. The transaction is subject to completion of due diligence review, customary definitive documentation, deal structure and requisite corporate and regulatory approvals. The final terms of the transaction will be available upon the execution of definitive documentation.

Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the proposed transaction with ProstaGene, the likelihood of closing the proposed transaction with ProstaGene, the Company’s clinical focus, and the Company’s current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, the Company urges investors to specifically consider the various risk factors identified in the Company’s Form 10-K for the fiscal year ended May31, 2017 in the section titled “Risk Factors” in Part I, Item 1A, as supplemented by its Form 10-Q for the quarterly period ended February28, 2018 in the section titled “Risk Factors” in Part II, Item 1A, any of which could cause actual results to differ materially from those indicated by the Company’s forward-looking statements.

The Company’s forward-looking statements reflect its current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. Investors should not place undue reliance on the Company’s forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i)the sufficiency of the Company’s cash position and the Company’s ongoing ability to raise additional capital to fund its operations, (ii)the Company’s ability to complete its Phase 2b/3 pivotal combination therapy trial for PRO 140 (CD02) and to meet the FDA’s requirements with respect to safety and efficacy to support the filing of a Biologics License Application, (iii)the Company’s ability to meet its debt obligations, if any, (iv)the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (v)the Company’s ability to achieve approval of a marketable product, (vi)design, implementation and conduct of clinical trials, (vii)the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (viii)the market for, and marketability of, any product that is approved, (ix)the existence or development of vaccines, drugs, or other treatments for infection with HIV that are viewed by medical professionals or patients as superior to the Company’s products, (x)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xi)general economic and business conditions, (xii)changes in foreign, political, and social conditions, and (xiii)various other matters, many of which are beyond the Company’s control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by the Company’s forward-looking statements.

The Company intends that all forward-looking statements made in this Current Report on Form 8-K will be subject to the safe harbor protection of the federal securities laws to Section27A of the Securities Act of 1933, as amended, to the extent applicable. Except as required by law, the Company does not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this Current Report on Form 8-K. Additionally, the Company does not undertake any responsibility to update investors upon the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

Item 5.02Financial Statements and Exhibits.


CytoDyn Inc. Exhibit
EX-99.1 2 d476247dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders     •   Announces non-binding Letter of Intent to acquire CCR5-focused cancer company ProstaGene LLC     •   Maintains commitment to advancing PRO 140 clinical programs in HIV and graft-versus-host disease     •   Advancing plans to submit BLA for PRO 140 in combination therapy for HIV VANCOUVER,…
To view the full exhibit click here

About CytoDyn Inc. (OTCMKTS:CYDY)

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

An ad to help with our costs